oltipraz has been researched along with Fibrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M; Hao, MH; Ma, XY; Sun, WP; Tang, Y; Zhu, HY | 1 |
| Cao, W; Chen, W; Ding, M; Guo, H; Lin, T; Wang, T; Wei, H; Yu, H; Zhang, C; Zhao, S; Zhao, X | 1 |
2 other study(ies) available for oltipraz and Fibrosis
| Article | Year |
|---|---|
Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cytokines; Disease Models, Animal; Fibrosis; Heart Failure; Inflammation Mediators; Isoproterenol; Myocytes, Cardiac; Oxidative Stress; Pyrazines; Rats, Sprague-Dawley; Recovery of Function; Thiones; Thiophenes; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Size and temporal-dependent efficacy of oltipraz-loaded PLGA nanoparticles for treatment of acute kidney injury and fibrosis.
Topics: Acute Kidney Injury; Animals; Antioxidants; Fibrosis; Mice; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Reperfusion Injury; Thiones; Thiophenes; Time Factors; Tissue Distribution; Treatment Outcome | 2019 |